abstract: PURPOSE: @entity55 is associated with a variety of diseases. @entity55 on in vivo imaging may facilitate the early detection and treatment of @entity358 . Although routinely used in thoracic imaging, computed tomography has thus far not been compellingly shown to characterize @entity32 in vivo. Alternatively, magnetic resonance imaging (MRI) is a nonionizing radiation technique to better visualize and characterize pulmonary tissue. Prior to routine adoption of MRI for early characterization of @entity32 in @entity1 , a rigorous and quantitative characterization of the utility of MRI to identify @entity32 is required. Such characterization may be achieved by considering ex vivo histology as the ground truth, since it enables the definitive spatial assessment of @entity32 . In this study, the authors introduce a novel framework to integrate 2D histology, ex vivo and in vivo imaging to enable the mapping of the extent of disease from ex vivo histology onto in vivo imaging, with the goal of facilitating computerized feature analysis and interrogation of disease appearance on in vivo imaging. The authors' framework was evaluated in a preclinical preliminary study aimed to identify computer extracted features on in vivo MRI associated with @entity55 . METHODS: The authors' image analytics framework first involves reconstructing the histologic volume in 3D from individual histology slices. Second, the authors map the disease ground truth onto in vivo MRI via coregistration with 3D histology using the ex vivo lung MRI as a conduit. Finally, computerized feature analysis of the disease extent is performed to identify candidate in vivo imaging signatures of disease presence and extent. RESULTS: The authors evaluated the framework by assessing the quality of the 3D histology reconstruction and the histology-MRI fusion, in the context of an initial use case involving characterization of @entity32 in a @entity19 model. The authors' evaluation considered three @entity19 , two with an @entity32 phenotype and one control. The authors' iterative 3D histology reconstruction yielded a 70.1%    2.7% overlap with the ex vivo MRI volume. Across a total of 17 anatomic landmarks manually delineated at the division of airways, the target registration error between the ex vivo MRI and 3D histology reconstruction was 0.85    0.44 mm, suggesting that a good alignment of the ex vivo 3D histology and ex vivo MRI had been achieved. The 3D histology-in vivo MRI coregistered volumes resulted in an overlap of 73.7%    0.9%. Preliminary computerized feature analysis was performed on an additional four control @entity19 , for a total of seven @entity19 considered in this study. Gabor texture filters appeared to best capture differences between the inflamed and noninflamed regions on MRI. CONCLUSIONS: The authors' 3D histology reconstruction and multimodal registration framework were successfully employed to reconstruct the histology volume of the lung and fuse it with in vivo MRI to create a ground truth map for @entity32 on in vivo MRI. The analytic platform presented here lays the framework for a rigorous validation of the identified imaging features for @entity55 on MRI in a large prospective cohort.

title: Framework for 3D histologic reconstruction and fusion with in vivo MRI: Preliminary results of XXXX in a @entity19 model.

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['chronic inflammation', 'inflammation']

entities_list: @entity55 :: ('MESH:D011014', 'Disease') :: ['Assessing pulmonary inflammation', 'chronic lung inflammation', 'Pulmonary inflammation', 'chronic pulmonary inflammation']

entities_list: @entity358 :: ('MESH:D008171', 'Disease') :: ['lung diseases']

answer: @entity55 :: (MESH:D011014,Disease) :: ['characterizing pulmonary inflammation']


abstract: PURPOSE: @entity55 is associated with a variety of diseases. @entity55 on in vivo imaging may facilitate the early detection and treatment of @entity358 . Although routinely used in thoracic imaging, computed tomography has thus far not been compellingly shown to characterize @entity32 in vivo. Alternatively, magnetic resonance imaging (MRI) is a nonionizing radiation technique to better visualize and characterize pulmonary tissue. Prior to routine adoption of MRI for early characterization of @entity32 in @entity1 , a rigorous and quantitative characterization of the utility of MRI to identify @entity32 is required. Such characterization may be achieved by considering ex vivo histology as the ground truth, since it enables the definitive spatial assessment of @entity32 . In this study, the authors introduce a novel framework to integrate 2D histology, ex vivo and in vivo imaging to enable the mapping of the extent of disease from ex vivo histology onto in vivo imaging, with the goal of facilitating computerized feature analysis and interrogation of disease appearance on in vivo imaging. The authors' framework was evaluated in a preclinical preliminary study aimed to identify computer extracted features on in vivo MRI associated with @entity55 . METHODS: The authors' image analytics framework first involves reconstructing the histologic volume in 3D from individual histology slices. Second, the authors map the disease ground truth onto in vivo MRI via coregistration with 3D histology using the ex vivo lung MRI as a conduit. Finally, computerized feature analysis of the disease extent is performed to identify candidate in vivo imaging signatures of disease presence and extent. RESULTS: The authors evaluated the framework by assessing the quality of the 3D histology reconstruction and the histology-MRI fusion, in the context of an initial use case involving characterization of @entity32 in a @entity19 model. The authors' evaluation considered three @entity19 , two with an @entity32 phenotype and one control. The authors' iterative 3D histology reconstruction yielded a 70.1%    2.7% overlap with the ex vivo MRI volume. Across a total of 17 anatomic landmarks manually delineated at the division of airways, the target registration error between the ex vivo MRI and 3D histology reconstruction was 0.85    0.44 mm, suggesting that a good alignment of the ex vivo 3D histology and ex vivo MRI had been achieved. The 3D histology-in vivo MRI coregistered volumes resulted in an overlap of 73.7%    0.9%. Preliminary computerized feature analysis was performed on an additional four control @entity19 , for a total of seven @entity19 considered in this study. Gabor texture filters appeared to best capture differences between the inflamed and noninflamed regions on MRI. CONCLUSIONS: The authors' 3D histology reconstruction and multimodal registration framework were successfully employed to reconstruct the histology volume of the lung and fuse it with in vivo MRI to create a ground truth map for @entity32 on in vivo MRI. The analytic platform presented here lays the framework for a rigorous validation of the identified imaging features for @entity55 on MRI in a large prospective cohort.

title: Framework for 3D histologic reconstruction and fusion with in vivo MRI: Preliminary results of @entity55 in a XXXX model.

answer: @entity19 :: (10090,Species) :: ['mouse']


abstract: AIM: To record in real life the appreciation of elderly @entity1 , their caregivers and physicians of a once daily formulation of prolonged release of @entity11545 in the treatment of mild to moderate @entity195 . METHODS: A prospective, multicenter, observational study was conducted in 128 elderly @entity1 , treated for 6 months with @entity11545 , @entity8124 or @entity11544 . RESULTS: Of the @entity1 treated with @entity11545 , 82 of the 97 (84.5%) were continuing their treatment after 6 months. These @entity1 reported their condition as improved in 49%, unchanged in 47% and worsened in 4%. Caregivers rated global evaluation as 37% better, 41% unchanged and 22% worse. Physicians rated global clinical impression of change as 46% better, 34% unchanged and 20% worse. Measurements of cognition and behavior remained stable. The appreciation of physicians and caregivers corresponded well (P<0.001). The incidence of serious side-effects possibly related to @entity11545 was 9.3%, which was not different from that in @entity1 treated with other cholinesterase inhibitors. CONCLUSION: In a real life setting, @entity11545 once daily is safe and is favorably appreciated by @entity1 , their caregivers and physicians.

title: @entity11545 ( @entity11545 ) once daily outcome and satisfaction survey (RODOS) in mild to moderate XXXX : a study in a real life population.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity11545 :: ('MESH:D005702', 'Chemical') :: ['galantamine']

entities_list: @entity11544 :: ('MESH:C072506', 'Chemical') :: ['rivastigmine']

entities_list: @entity195 :: ('MESH:D000544', 'Disease') :: ["Alzheimer's disease"]

entities_list: @entity8124 :: ('MESH:C076946', 'Chemical') :: ['donepezil']

answer: @entity195 :: (MESH:D000544,Disease) :: ['Alzheimer's disease']


abstract: AIM: To record in real life the appreciation of elderly @entity1 , their caregivers and physicians of a once daily formulation of prolonged release of @entity11545 in the treatment of mild to moderate @entity195 . METHODS: A prospective, multicenter, observational study was conducted in 128 elderly @entity1 , treated for 6 months with @entity11545 , @entity8124 or @entity11544 . RESULTS: Of the @entity1 treated with @entity11545 , 82 of the 97 (84.5%) were continuing their treatment after 6 months. These @entity1 reported their condition as improved in 49%, unchanged in 47% and worsened in 4%. Caregivers rated global evaluation as 37% better, 41% unchanged and 22% worse. Physicians rated global clinical impression of change as 46% better, 34% unchanged and 20% worse. Measurements of cognition and behavior remained stable. The appreciation of physicians and caregivers corresponded well (P<0.001). The incidence of serious side-effects possibly related to @entity11545 was 9.3%, which was not different from that in @entity1 treated with other cholinesterase inhibitors. CONCLUSION: In a real life setting, @entity11545 once daily is safe and is favorably appreciated by @entity1 , their caregivers and physicians.

title: XXXX ( @entity11545 ) once daily outcome and satisfaction survey (RODOS) in mild to moderate @entity195 : a study in a real life population.

answer: @entity11545 :: (MESH:D005702,Chemical) :: ['Galantamine']


abstract: AIM: To record in real life the appreciation of elderly @entity1 , their caregivers and physicians of a once daily formulation of prolonged release of @entity11545 in the treatment of mild to moderate @entity195 . METHODS: A prospective, multicenter, observational study was conducted in 128 elderly @entity1 , treated for 6 months with @entity11545 , @entity8124 or @entity11544 . RESULTS: Of the @entity1 treated with @entity11545 , 82 of the 97 (84.5%) were continuing their treatment after 6 months. These @entity1 reported their condition as improved in 49%, unchanged in 47% and worsened in 4%. Caregivers rated global evaluation as 37% better, 41% unchanged and 22% worse. Physicians rated global clinical impression of change as 46% better, 34% unchanged and 20% worse. Measurements of cognition and behavior remained stable. The appreciation of physicians and caregivers corresponded well (P<0.001). The incidence of serious side-effects possibly related to @entity11545 was 9.3%, which was not different from that in @entity1 treated with other cholinesterase inhibitors. CONCLUSION: In a real life setting, @entity11545 once daily is safe and is favorably appreciated by @entity1 , their caregivers and physicians.

title: @entity11545 ( XXXX ) once daily outcome and satisfaction survey (RODOS) in mild to moderate @entity195 : a study in a real life population.

answer: @entity11545 :: (MESH:D005702,Chemical) :: ['Reminyl']


abstract: OBJECTIVE: To study the association between @entity2208 in @entity309 ( @entity309 ) @entity1 and serologic findings, disease activity, and antirheumatic drug treatment, and to study disease activity and reproductive outcomes after a @entity2208 . METHODS: Within a nationwide prospective cohort study (Pregnancy-Induced Amelioration of @entity309 study), @entity1 with @entity309 were followed up from preconception until 6 months after delivery or @entity2208 . Univariate and logistic regression analyses were performed to assess variables of interest, with covariates included in the models if the P value for association with @entity2208 was <0.20 and subsequently excluded if the P value was >0.10. RESULTS: Among 162 pregnancies, 28 @entity2208 occurred (17.3%; 95% confidence interval 12.2-24.0%). @entity1 who miscarried were older than @entity1 with an ongoing pregnancy. @entity1 who miscarried tended to be more often positive for anti-citrullinated protein antibodies (ACPAs), to have higher disease activity scores, and to have more often received @entity1499 ( @entity6822 ) therapy in the past. Logistic regression showed a tendency toward a higher likelihood of @entity2208 in association with increasing age (P   =   0.065) and presence of ACPAs (P   =   0.092). After @entity2208 , 33% of @entity1 had a flare of @entity309 . Within 1 year, 68% of @entity1 became pregnant again, 14% stopped trying to conceive, and 11% were lost to followup. The live birth rate of the subsequent pregnancy was 90%. CONCLUSION: The @entity2208 rate in the @entity33934 cohort is comparable to that in the general population. Due to the low frequency of @entity2208 in this study, the associations between @entity2208 in @entity309 and the presence of ACPAs, disease activity, and @entity6822 use did not reach statistical significance. Within 1 year after @entity2208 , the majority of @entity1 who continued trying to conceive achieved a pregnancy resulting in a live birth.

title: Brief Report: Miscarriages in Female XXXX @entity1 : Associations With Serologic Findings, Disease Activity, and Antirheumatic Drug Treatment.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'Women']

entities_list: @entity2208 :: ('MESH:D000022', 'Disease') :: ['miscarriage', 'miscarriages']

entities_list: @entity1499 :: ('MESH:D008727', 'Chemical') :: ['methotrexate']

entities_list: @entity309 :: ('MESH:D001172', 'Disease') :: ['rheumatoid arthritis', 'RA']

answer: @entity309 :: (MESH:D001172,Disease) :: ['Rheumatoid Arthritis']


abstract: OBJECTIVE: To study the association between @entity2208 in @entity309 ( @entity309 ) @entity1 and serologic findings, disease activity, and antirheumatic drug treatment, and to study disease activity and reproductive outcomes after a @entity2208 . METHODS: Within a nationwide prospective cohort study (Pregnancy-Induced Amelioration of @entity309 study), @entity1 with @entity309 were followed up from preconception until 6 months after delivery or @entity2208 . Univariate and logistic regression analyses were performed to assess variables of interest, with covariates included in the models if the P value for association with @entity2208 was <0.20 and subsequently excluded if the P value was >0.10. RESULTS: Among 162 pregnancies, 28 @entity2208 occurred (17.3%; 95% confidence interval 12.2-24.0%). @entity1 who miscarried were older than @entity1 with an ongoing pregnancy. @entity1 who miscarried tended to be more often positive for anti-citrullinated protein antibodies (ACPAs), to have higher disease activity scores, and to have more often received @entity1499 ( @entity6822 ) therapy in the past. Logistic regression showed a tendency toward a higher likelihood of @entity2208 in association with increasing age (P   =   0.065) and presence of ACPAs (P   =   0.092). After @entity2208 , 33% of @entity1 had a flare of @entity309 . Within 1 year, 68% of @entity1 became pregnant again, 14% stopped trying to conceive, and 11% were lost to followup. The live birth rate of the subsequent pregnancy was 90%. CONCLUSION: The @entity2208 rate in the @entity33934 cohort is comparable to that in the general population. Due to the low frequency of @entity2208 in this study, the associations between @entity2208 in @entity309 and the presence of ACPAs, disease activity, and @entity6822 use did not reach statistical significance. Within 1 year after @entity2208 , the majority of @entity1 who continued trying to conceive achieved a pregnancy resulting in a live birth.

title: Brief Report: Miscarriages in Female @entity309 XXXX : Associations With Serologic Findings, Disease Activity, and Antirheumatic Drug Treatment.

answer: @entity1 :: (9606,Species) :: ['Patients']


abstract: STUDY OBJECTIVE: To investigate the rate of @entity322 ( @entity322 ) in a sample of young nulligravid @entity1 and its potential risk factors and consequences on life habits. DESIGN AND @entity1 : The study is based on an online self-administered questionnaire taken by nulligravid @entity1 aged 15 to 25  years. MEASUREMENTS: The Questionnaire for @entity322 and part of The King's Health Questionnaire. Demographics and general characteristics are also recorded. RESULTS: We collected 1936 questionnaires (mean age of @entity1 , 21  years); 12.4% of the sample reported any @entity322 (95% confidence interval [CI] 10.9% to 13.9%). The estimated incidence of @entity322 subtypes was 7.2% (95% CI 6.0% to 8.4%) stress @entity322 , 3.4% (95% CI 2.6% to 4.3%) urge @entity322 , and 1.9% (95% CI 1.3% to 2.6%) mixed @entity322 . Age younger than 19  years and body mass index of 30  kg/m(2) or greater were associated in the multivariate analysis with an increased risk of @entity322 . A self-reported history of @entity74 increased the risk of @entity322 (adjusted odds ratio [AOR] 1.4 and 95% CI 1.1% to 1.9%), without significant differences among the @entity322 subtypes. A current history of constipation (AOR 1.9 and 95% CI 1.3% to 2.6%) and enuresis after the age of 5 also increased the risk of @entity322 (AOR 2.9 and 95% CI 2.0% to 4.3%). CONCLUSION: In a sample of young nulligravid @entity1 , @entity322 was not associated with any chronic risk factor known for elder age, but a prevention program may be proposed to @entity1 because of their young age (eg, educational session to promote the proper functioning of the pelvic floor). More detailed analyses are needed to better assess the prevalence of @entity322 and risk factors in young nulligravid @entity1 .

title: Frequency and Determinants of Urinary Incontinence in Adolescent and Young Nulliparous XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'women', 'PARTICIPANTS']

entities_list: @entity322 :: ('MESH:D014549', 'Disease') :: ['urinary incontinence', 'UI', 'Urinary Incontinence Diagnosis']

entities_list: @entity74 :: ('MESH:D030342', 'Disease') :: ['psychological disorders']

answer: @entity1 :: (9606,Species) :: ['Women']


abstract: OBJECTIVE:     To describe our experience with @entity1625 ( @entity1625 ) for @entity703 and compare the outcomes with @entity1625 performed for single masses. @entity1 AND METHODS:     Retrospective analysis of medical records of @entity1 undergoing @entity1625 at our institution between 2005 and 2009 was performed.     The cohort was divided in two groups based on @entity5 focality: group 1, @entity1625 for a @entity5 (n= 99) and group 2, @entity1625 for multiple @entity5 (n= 12).     The groups were compared with regards to demographic and peri-operative variables. RESULTS:     Demographic variables were not different between the groups. Median dominant @entity5 size was 3.1 cm (interquartile range [IQR] 2.4-4.0) and 4.0 cm (2.3-5.9) in groups 1 and 2, respectively.     Median secondary @entity5 size in group 2 was 1.0 cm (1.0-1.8).     Operative times were longer in group 2 compared with group 1 (220 vs 160 min, P= 0.009).     Warm ischaemia times (WIT) (23 vs 22 min) and estimated @entity190 (EBL) (100 vs 85 mL) were similar. CONCLUSIONS:     @entity1625 is a viable option for the treatment of multiple @entity703 .     Peri-operative outcomes are similar to standard @entity1625 with the exception of longer operative time.     In experienced hands, the advantages of minimally invasive surgery may be extended to select @entity1 with @entity703 .

title: Laparoscopic partial nephrectomy for XXXX : feasibility and analysis of peri-operative outcomes.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS']

entities_list: @entity1625 :: ('MESH:D004828', 'Disease') :: ['laparoscopic partial nephrectomy', 'LPN']

entities_list: @entity190 :: ('MESH:D006473', 'Disease') :: ['blood loss']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['ipsilateral tumours', 'single tumour', 'tumour']

entities_list: @entity703 :: ('MESH:D007680', 'Disease') :: ['ipsilateral multifocal renal tumours', 'multiple kidney tumours', 'ipsilateral renal tumours']

answer: @entity5 :: (MESH:D009369,Disease) :: ['multiple tumours']


abstract: We performed exome analysis in two affected siblings with severe @entity717 ( @entity717 ), @entity4242 and @entity508 from an Ashkenazi Jewish consanguineous family. We identified only one rare variant, a missense in @entity19498 ( @entity72047 [ @entity72048 ]), that is homozygous in both siblings but not in any of their 11 unaffected siblings or their parents (Logarithm of odds, LOD score: 2.6). This variant is predicted damaging. We genotyped 450 controls of Ashkenazi Jewish ancestry and identified only 5 individuals who are heterozygous for this variant (minor allele frequency: 0.0056). @entity19498 ( @entity19498 ) encodes a transporter for neutral aminoacids such as @entity3929 , @entity563 , @entity462 and @entity1889 . @entity18242 is essential for neuronal survival and differentiation. Indeed, @entity18242 biosynthesis disorders affect brain development and cause severe @entity717 . In the brain, @entity18242 is synthesized in astrocytes but not in neurons. It has been proposed that @entity19498 mediates the uptake of @entity18242 into neurons and the release of glia-borne @entity18242 to neighboring cells. @entity19498 disruption may thus impair brain development and function by decreasing the levels of @entity18242 in neurons. The identification of additional families with mutations in @entity19498 would be necessary to confirm its involvement in @entity717 .

title: A homozygous mutation in XXXX in siblings with severe @entity717 and @entity4242 .

entities_list: @entity462 :: ('MESH:D003545', 'Chemical') :: ['cysteine']

entities_list: @entity563 :: ('CHEBI:17822', 'Chemical') :: ['serine']

entities_list: @entity508 :: ('MESH:D009128', 'Disease') :: ['spasticity']

entities_list: @entity18242 :: ('CHEBI:33384', 'Chemical') :: ['L-Serine', 'L-serine']

entities_list: @entity4242 :: ('MESH:D008831', 'Disease') :: ['microcephaly']

entities_list: @entity717 :: ('MESH:D009069', 'Disease') :: ['ID', 'intellectual disability']

entities_list: @entity1889 :: ('CHEBI:26986', 'Chemical') :: ['threonine']

answer: @entity19498 :: (6509,Gene) :: ['SLC1A4']


abstract: We performed exome analysis in two affected siblings with severe @entity717 ( @entity717 ), @entity4242 and @entity508 from an Ashkenazi Jewish consanguineous family. We identified only one rare variant, a missense in @entity19498 ( @entity72047 [ @entity72048 ]), that is homozygous in both siblings but not in any of their 11 unaffected siblings or their parents (Logarithm of odds, LOD score: 2.6). This variant is predicted damaging. We genotyped 450 controls of Ashkenazi Jewish ancestry and identified only 5 individuals who are heterozygous for this variant (minor allele frequency: 0.0056). @entity19498 ( @entity19498 ) encodes a transporter for neutral aminoacids such as @entity3929 , @entity563 , @entity462 and @entity1889 . @entity18242 is essential for neuronal survival and differentiation. Indeed, @entity18242 biosynthesis disorders affect brain development and cause severe @entity717 . In the brain, @entity18242 is synthesized in astrocytes but not in neurons. It has been proposed that @entity19498 mediates the uptake of @entity18242 into neurons and the release of glia-borne @entity18242 to neighboring cells. @entity19498 disruption may thus impair brain development and function by decreasing the levels of @entity18242 in neurons. The identification of additional families with mutations in @entity19498 would be necessary to confirm its involvement in @entity717 .

title: A homozygous mutation in @entity19498 in siblings with severe @entity717 and XXXX .

answer: @entity4242 :: (MESH:D008831,Disease) :: ['microcephaly']


abstract: We performed exome analysis in two affected siblings with severe @entity717 ( @entity717 ), @entity4242 and @entity508 from an Ashkenazi Jewish consanguineous family. We identified only one rare variant, a missense in @entity19498 ( @entity72047 [ @entity72048 ]), that is homozygous in both siblings but not in any of their 11 unaffected siblings or their parents (Logarithm of odds, LOD score: 2.6). This variant is predicted damaging. We genotyped 450 controls of Ashkenazi Jewish ancestry and identified only 5 individuals who are heterozygous for this variant (minor allele frequency: 0.0056). @entity19498 ( @entity19498 ) encodes a transporter for neutral aminoacids such as @entity3929 , @entity563 , @entity462 and @entity1889 . @entity18242 is essential for neuronal survival and differentiation. Indeed, @entity18242 biosynthesis disorders affect brain development and cause severe @entity717 . In the brain, @entity18242 is synthesized in astrocytes but not in neurons. It has been proposed that @entity19498 mediates the uptake of @entity18242 into neurons and the release of glia-borne @entity18242 to neighboring cells. @entity19498 disruption may thus impair brain development and function by decreasing the levels of @entity18242 in neurons. The identification of additional families with mutations in @entity19498 would be necessary to confirm its involvement in @entity717 .

title: A homozygous mutation in @entity19498 in siblings with severe XXXX and @entity4242 .

answer: @entity717 :: (MESH:D009069,Disease) :: ['intellectual disability']


abstract: INTRODUCTION: Specimens of @entity1 immature permanent teeth after @entity11624 ( @entity11624 ) are sparse. This case report describes the histologic and immunohistochemical findings of tissue formed in the canal space of a @entity1 immature permanent tooth with @entity1546 after @entity11624 . METHODS: A @entity1 presenting with immature @entity1 permanent tooth #29  with @entity1546 underwent @entity11624 . At the 10-month follow-up visit, radiographic examination revealed @entity1548 , marked narrowing of the apical foramen, increased thickness of the canal walls, and minimal lengthening of the root. Notably, the tooth regained pulp sensibility. Tooth #29 was extracted for orthodontic reasons and processed for histologic and immunohistochemical examination. RESULTS: The canal space was filled with newly formed cementumlike tissue, bonelike tissue, and fibrous connective tissue. The apical closure, thickness, and length increment of the root were caused by the deposition of cementumlike tissue without dentin. Furthermore, neurons and nerve fibers were observed in the canal space; this observation was confirmed by immunohistochemistry. CONCLUSIONS: Based on the findings in the present case, after @entity11624 , the newly formed tissues in the canal space of the @entity1 immature permanent tooth with @entity1546 were primarily fibrous connective tissue, cementumlike tissue, and bonelike tissue. Nerve regeneration was identified.

title: Histologic and Immunohistochemical Findings of a @entity1 Immature Permanent Tooth with XXXX after Regenerative Endodontic Treatment.

entities_list: @entity1 :: ('9606', 'Species') :: ['human', 'patient']

entities_list: @entity1546 :: ('MESH:D010485', 'Disease') :: ['apical periodontitis']

entities_list: @entity11624 :: ('MESH:D011671', 'Disease') :: ['RET', 'regenerative endodontic treatment']

entities_list: @entity1548 :: ('MESH:D010483', 'Disease') :: ['complete resolution of the periapical lesion']

answer: @entity1546 :: (MESH:D010485,Disease) :: ['Apical Periodontitis']


abstract: INTRODUCTION: Specimens of @entity1 immature permanent teeth after @entity11624 ( @entity11624 ) are sparse. This case report describes the histologic and immunohistochemical findings of tissue formed in the canal space of a @entity1 immature permanent tooth with @entity1546 after @entity11624 . METHODS: A @entity1 presenting with immature @entity1 permanent tooth #29  with @entity1546 underwent @entity11624 . At the 10-month follow-up visit, radiographic examination revealed @entity1548 , marked narrowing of the apical foramen, increased thickness of the canal walls, and minimal lengthening of the root. Notably, the tooth regained pulp sensibility. Tooth #29 was extracted for orthodontic reasons and processed for histologic and immunohistochemical examination. RESULTS: The canal space was filled with newly formed cementumlike tissue, bonelike tissue, and fibrous connective tissue. The apical closure, thickness, and length increment of the root were caused by the deposition of cementumlike tissue without dentin. Furthermore, neurons and nerve fibers were observed in the canal space; this observation was confirmed by immunohistochemistry. CONCLUSIONS: Based on the findings in the present case, after @entity11624 , the newly formed tissues in the canal space of the @entity1 immature permanent tooth with @entity1546 were primarily fibrous connective tissue, cementumlike tissue, and bonelike tissue. Nerve regeneration was identified.

title: Histologic and Immunohistochemical Findings of a XXXX Immature Permanent Tooth with @entity1546 after Regenerative Endodontic Treatment.

answer: @entity1 :: (9606,Species) :: ['Human']


abstract: OBJECTIVE: To investigate the effect of @entity25 on functional and social outcomes after mild @entity131 . SETTING: Outpatient @entity131 clinic in a tertiary @entity130 center. @entity1 : A total of 374 mild @entity131 @entity1 were assessed within 3 months of injury and followed up every 3 months for 1 year. DESIGN: Analysis of a historical cohort in a naturalistic clinical setting. MAIN MEASURES: At each visit, symptoms of concussion and @entity458 and indices of functional and social outcomes were measured with the Rivermead Postconcussion Questionnaire, 28-item General Health Questionnaire, and @entity542 Follow-up Questionnaire, respectively. Changes in outcome scores over time were explored using repeated measures analysis of variance and compared between subjects with persistent (SD) and recovered (SR) @entity25 . Predictors of functional/social outcome were determined using linear regression. RESULTS: The percentages of subjects reporting @entity25 at each time point were 71.9%, 57.2%, 55.1%, and 53.7%, respectively. For functional and social outcomes, significant effects of time (F3,315 = 9.54; P < .001), group (SD vs SR) F1,317 = 5.32; P = .022, and time X group interaction F3,315 = 4.14; P = .007 were found. Persistent @entity25 (P = 0.011) and higher symptom burden at 6 months postinjury (P < .0001) were independent predictors of poorer outcome. CONCLUSION: Sleep disturbance, independent of @entity458 , is an important prognostic factor of functional and social outcomes after mild @entity131 .

title: Persistent Sleep Disturbances Independently Predict Poorer Functional and Social Outcomes 1 Year After Mild XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'PARTICIPANTS']

entities_list: @entity131 :: ('MESH:D001930', 'Disease') :: ['traumatic brain injury']

entities_list: @entity542 :: ('MESH:D006259', 'Disease') :: ['Rivermead Head Injury']

entities_list: @entity458 :: ('MESH:D020018', 'Disease') :: ['psychological distress']

entities_list: @entity25 :: ('MESH:D012893', 'Disease') :: ['sleep disturbance', 'sleep disturbances']

answer: @entity131 :: (MESH:D001930,Disease) :: ['Traumatic Brain Injury']


abstract: PURPOSE: @entity63 -reperfusion injury is unavoidable during organ transplantation. Prolonged @entity63 -reperfusion injury is detrimental to short-term and long-term graft function and survival. @entity3958 is a recently characterized, endogenously produced gaseous molecule with important physiological roles that has been shown to be cytoprotective during tissue @entity63 -reperfusion injury. The current study aimed to determine whether @entity3958 could mitigate cold @entity8 in the clinically relevant context of allogeneic renal transplantation. MATERIALS AND METHODS: Following bilateral native nephrectomy Lewis @entity35 underwent renal transplantation with kidneys from Brown Norway donor @entity35 that were flushed with cold (4C) standard University of Wisconsin preservation solution (University of Wisconsin preservation solution group) or cold University of Wisconsin preservation solution plus 150  M @entity8835 ( @entity3958 group) solution. Kidneys were stored for 6 hours at 4C in the same solution. Recipient animals were monitored for 14 days or until sacrifice using metabolic cages to assess various parameters of renal graft function. RESULTS: @entity3958 treatment improved early allograft survival and function, and decreased early levels of @entity39 , apoptosis and @entity26493 compared to University of Wisconsin preservation solution alone. @entity3958 treatment did not affect allograft rejection. Rather, it modulated the early allograft transcriptome to decrease the expression of @entity8 , coagulation and cellular stress response genes, and increase the expression of cellular proliferation and Ifn-y induced genes compared to University of Wisconsin preservation solution alone. CONCLUSIONS: To our knowledge our findings are the first to show that @entity3958 protects donor kidneys against @entity63 -reperfusion injury in the context of allogeneic renal transplantation. This potentially represents a novel cost-effective therapeutic solution to mitigate @entity63 -reperfusion injury and improve the clinical outcomes of renal transplantation.

title: Hydrogen Sulfide Treatment Mitigates XXXX during Cold Storage and Improves Early Transplant Kidney Function and Survival Following Allogeneic Renal Transplantation.

entities_list: @entity8 :: ('MESH:D007674', 'Disease') :: ['renal ischemia-reperfusion injury', 'renal injury']

entities_list: @entity63 :: ('MESH:D007511', 'Disease') :: ['Ischemia', 'cold ischemia', 'ischemia']

entities_list: @entity39 :: ('MESH:D009336', 'Disease') :: ['necrosis']

answer: @entity8 :: (MESH:D007674,Disease) :: ['Renal Allograft Ischemia-Reperfusion Injury']


abstract: UNASSIGNED: @entity3167 levels of therapeutic glycoprotein play an important role in plasma half-life. An undesirable decrease of @entity3167 content was observed when we increased Fc-fusion protein productivity fourfold in a GS-CHO cell line by bioprocess optimization. We investigated the potential mechanism for the @entity3167 content reduction. We found that limited @entity20561 precursor and the extracellular sialidase were not responsible for the reduction of the @entity3167 content after titer improvement. Oligosaccharide analysis revealed that the lack of protein galactosylation was the potential cause for the reduction of @entity3167 content. Thus we validated this notion by evaluated @entity3649 supplementation in 2  L bioreactors. Cell culture performance was not impacted by addition of up to 40  mM @entity3649 except for the @entity413 consumption rate. Addition of 20  mM @entity3649 to the bioreactor resulted in the increase of 44  % for total @entity3167 content and 20.3  % for sialylated glycans. These data were further validated when the process was run on 200  L scaled bioreactor. These data together show that the galactosylation plays an apparent role in sialylation in our current system.

title: XXXX supplementation enhance sialylation of recombinant Fc-fusion protein in CHO cell: an insight into the role of galactosylation in sialylation.

entities_list: @entity20561 :: ('CHEBI:25609', 'Chemical') :: ['nucleotide sugar']

entities_list: @entity3167 :: ('MESH:D019158', 'Chemical') :: ['Sialic acid', 'sialic acid']

entities_list: @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']

entities_list: @entity3649 :: ('MESH:D005690', 'Chemical') :: ['galactose']

answer: @entity3649 :: (MESH:D005690,Chemical) :: ['Galactose']


abstract: OBJECTIVE: The purpose is to exam whether excess body weight is associated with an increased risk of @entity204 from unnatural causes, particularly, injury. METHOD: We analyzed nationally representative data of 14,453 adults (19 and older) who participated in the third National Health and Nutrition Examination Survey, 1988-1994, and were followed up with vital statuses through December 31, 2006. We used Cox proportional hazard regression to estimate the hazard ratio (HR) of @entity204 from all unnatural causes combined and specific ones. Gray's test was performed to assess the equality of cumulative incidence functions between body mass index (BMI) levels. RESULTS: A total of 128 unnatural deaths were recorded during an 18-year follow-up with 193,019 @entity1 -years accumulated. Compared with healthy weight @entity1 , a @entity1 with excess body weight had a low hazard of @entity204 from unnatural causes [HR=1.00 (reference), 0.58 (0.39-0.87), and 0.50 (0.30-0.82) for healthy weight, overweight and @entity28 @entity1 , respectively]. Injuries, including motor @entity64 and @entity998 , were the major types of unnatural deaths (n=91, 71% of all unnatural deaths), and the risk of @entity204 from @entity130 was linearly and reversely associated with BMI. The @entity130 were 1.00 (reference), 0.57 (0.36-0.91), and 0.36 (0.19-0.69) for healthy weight, overweight and @entity28 @entity1 , respectively. All these estimates were obtained after adjustment of socio-demographic variables. DISCUSSION: Excess body weight appears to be associated with a low risk of @entity204 from unnatural causes, particularly, @entity130 . Additional investigations on the mechanism underlying the relationship between BMI and unnatural deaths are warranted.

title: The relationship between excess body weight and the risk of XXXX from unnatural causes.

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'person']

entities_list: @entity64 :: ('MESH:D020521', 'Disease') :: ['vehicle accidents']

entities_list: @entity130 :: ('MESH:D014947', 'Disease') :: ['injuries', 'HRs of injury']

answer: @entity204 :: (MESH:D003643,Disease) :: ['death']


abstract: BACKGROUND: @entity102 contribute a large share of disease burden in low- and middle-income countries (LMICs). @entity102 have a tendency to occur simultaneously and where there are two or more such conditions, this is termed as 'multimorbidity'. Multimorbidity is associated with adverse health outcomes, but limited research has been undertaken in LMICs. Therefore, this study examines the prevalence and correlates of multimorbidity as well as the associations between multimorbidity and self-rated health, activities of daily living (ADLs), quality of life, and @entity308 across six LMICs. METHODS: Data was obtained from the WHO's Study on global AGEing and adult health ( @entity12337 ) @entity13830 (2007/10). This was a cross-sectional population based survey performed in LMICs, namely China, Ghana, India, Mexico, Russia, and South Africa, including 42,236 adults aged 18 years and older. Multimorbidity was measured as the simultaneous presence of two or more of eight chronic conditions including @entity951 , @entity625 , @entity565 , @entity1030 , @entity6 , @entity101 , @entity64 , and @entity227 . Associations with four health outcomes were examined, namely ADL limitation, self-rated health, @entity308 , and a quality of life index. Random-intercept multilevel regression models were used on pooled data from the six countries. RESULTS: The prevalence of morbidity and multimorbidity was 54.2 % and 21.9 %, respectively, in the pooled sample of six countries. Russia had the highest prevalence of multimorbidity (34.7 %) whereas China had the lowest (20.3 %). The likelihood of multimorbidity was higher in older age groups and was lower in those with higher socioeconomic status. In the pooled sample, the prevalence of 1+ ADL limitation was 14 %, @entity308 5.7 %, self-rated poor health 11.6 %, and mean quality of life score was 54.4. Substantial cross-country variations were seen in the four health outcome measures. The prevalence of 1+ ADL limitation, poor self-rated health, and @entity308 increased whereas quality of life declined markedly with an increase in number of diseases. CONCLUSIONS: Findings highlight the challenge of multimorbidity in LMICs, particularly among the lower socioeconomic groups, and the pressing need for reorientation of health care resources considering the distribution of multimorbidity and its adverse effect on health outcomes.

title: The impact of multimorbidity on adult physical and mental health in low- and middle-income countries: what does the study on global ageing and adult health ( XXXX ) reveal?

entities_list: @entity227 :: ('MESH:D014786', 'Disease') :: ['vision impairment']

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['depression']

entities_list: @entity625 :: ('MESH:D001168', 'Disease') :: ['arthritis']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes mellitus']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension']

entities_list: @entity102 :: ('MESH:D002908', 'Disease') :: ['Chronic diseases']

entities_list: @entity951 :: ('MESH:D000787', 'Disease') :: ['angina pectoris']

entities_list: @entity1030 :: ('MESH:D029424', 'Disease') :: ['chronic lung disease']

answer: @entity12337 :: (55511,Gene) :: ['SAGE']


abstract: UNASSIGNED: @entity8932 ( @entity8932 )-mediated signaling cascades and gene regulation are mainly involved in diseases such as immunity and @entity32 . In this study microarray analysis was performed using bone marrow-derived macrophages (BMDM) and Raw 264.7 cells to identify novel proteins involved in the @entity8932 -mediated cellular response. We found that pleckstrin homology-like domain family, member 1 ( @entity72049 ) is a novel gene up-regulated by @entity8932 stimulation and determined the unique signaling pathway for its expression. Treatment with @entity8932 agonist Pam3 CSK4 increased mRNA, protein, and fluorescence staining of @entity72049 . Induction of @entity72049 by @entity8932 stimulation disappeared from @entity8932 KO @entity19 -derived BMDM. Among janus kinase (JAK) family members, @entity16404 was involved in @entity8932 -stimulated @entity72049 expression. @entity10433 ( @entity10433 ) also participated in @entity72049 expression downstream of the @entity16404 . Interestingly, @entity8837 was an intermediate between @entity16404 and @entity10433 . In silico analysis revealed the presence of highly conserved y-activated sites within @entity19 @entity72049 promoter and confirmed the @entity16404 - @entity10433 pathway is important to Pam3 CSK4 -induced @entity72049 transcription. These findings suggest that the @entity16404 - @entity8837 - @entity10433 pathway is an important signaling pathway for @entity72049 expression and that these proteins may play a critical role in eliciting @entity8932 -mediated immune and inflammatory response. This article is protected by copyright. All rights reserved.

title: Regulation of XXXX Expression by @entity16404 - @entity8837 - @entity10433 Signaling Pathway.

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation']

entities_list: @entity10433 :: ('20848(Tax:10090)', 'Gene') :: ['Signal transducer and activator of transcription 3', 'STAT3']

answer: @entity72049 :: (21664(Tax:10090),Gene) :: ['PHLDA1']


abstract: UNASSIGNED: @entity8932 ( @entity8932 )-mediated signaling cascades and gene regulation are mainly involved in diseases such as immunity and @entity32 . In this study microarray analysis was performed using bone marrow-derived macrophages (BMDM) and Raw 264.7 cells to identify novel proteins involved in the @entity8932 -mediated cellular response. We found that pleckstrin homology-like domain family, member 1 ( @entity72049 ) is a novel gene up-regulated by @entity8932 stimulation and determined the unique signaling pathway for its expression. Treatment with @entity8932 agonist Pam3 CSK4 increased mRNA, protein, and fluorescence staining of @entity72049 . Induction of @entity72049 by @entity8932 stimulation disappeared from @entity8932 KO @entity19 -derived BMDM. Among janus kinase (JAK) family members, @entity16404 was involved in @entity8932 -stimulated @entity72049 expression. @entity10433 ( @entity10433 ) also participated in @entity72049 expression downstream of the @entity16404 . Interestingly, @entity8837 was an intermediate between @entity16404 and @entity10433 . In silico analysis revealed the presence of highly conserved y-activated sites within @entity19 @entity72049 promoter and confirmed the @entity16404 - @entity10433 pathway is important to Pam3 CSK4 -induced @entity72049 transcription. These findings suggest that the @entity16404 - @entity8837 - @entity10433 pathway is an important signaling pathway for @entity72049 expression and that these proteins may play a critical role in eliciting @entity8932 -mediated immune and inflammatory response. This article is protected by copyright. All rights reserved.

title: Regulation of @entity72049 Expression by XXXX - @entity8837 - @entity10433 Signaling Pathway.

answer: @entity16404 :: (16452(Tax:10090),Gene) :: ['JAK2']


abstract: UNASSIGNED: @entity8932 ( @entity8932 )-mediated signaling cascades and gene regulation are mainly involved in diseases such as immunity and @entity32 . In this study microarray analysis was performed using bone marrow-derived macrophages (BMDM) and Raw 264.7 cells to identify novel proteins involved in the @entity8932 -mediated cellular response. We found that pleckstrin homology-like domain family, member 1 ( @entity72049 ) is a novel gene up-regulated by @entity8932 stimulation and determined the unique signaling pathway for its expression. Treatment with @entity8932 agonist Pam3 CSK4 increased mRNA, protein, and fluorescence staining of @entity72049 . Induction of @entity72049 by @entity8932 stimulation disappeared from @entity8932 KO @entity19 -derived BMDM. Among janus kinase (JAK) family members, @entity16404 was involved in @entity8932 -stimulated @entity72049 expression. @entity10433 ( @entity10433 ) also participated in @entity72049 expression downstream of the @entity16404 . Interestingly, @entity8837 was an intermediate between @entity16404 and @entity10433 . In silico analysis revealed the presence of highly conserved y-activated sites within @entity19 @entity72049 promoter and confirmed the @entity16404 - @entity10433 pathway is important to Pam3 CSK4 -induced @entity72049 transcription. These findings suggest that the @entity16404 - @entity8837 - @entity10433 pathway is an important signaling pathway for @entity72049 expression and that these proteins may play a critical role in eliciting @entity8932 -mediated immune and inflammatory response. This article is protected by copyright. All rights reserved.

title: Regulation of @entity72049 Expression by @entity16404 - @entity8837 - XXXX Signaling Pathway.

answer: @entity10433 :: (20848(Tax:10090),Gene) :: ['STAT3']


abstract: UNASSIGNED: @entity8932 ( @entity8932 )-mediated signaling cascades and gene regulation are mainly involved in diseases such as immunity and @entity32 . In this study microarray analysis was performed using bone marrow-derived macrophages (BMDM) and Raw 264.7 cells to identify novel proteins involved in the @entity8932 -mediated cellular response. We found that pleckstrin homology-like domain family, member 1 ( @entity72049 ) is a novel gene up-regulated by @entity8932 stimulation and determined the unique signaling pathway for its expression. Treatment with @entity8932 agonist Pam3 CSK4 increased mRNA, protein, and fluorescence staining of @entity72049 . Induction of @entity72049 by @entity8932 stimulation disappeared from @entity8932 KO @entity19 -derived BMDM. Among janus kinase (JAK) family members, @entity16404 was involved in @entity8932 -stimulated @entity72049 expression. @entity10433 ( @entity10433 ) also participated in @entity72049 expression downstream of the @entity16404 . Interestingly, @entity8837 was an intermediate between @entity16404 and @entity10433 . In silico analysis revealed the presence of highly conserved y-activated sites within @entity19 @entity72049 promoter and confirmed the @entity16404 - @entity10433 pathway is important to Pam3 CSK4 -induced @entity72049 transcription. These findings suggest that the @entity16404 - @entity8837 - @entity10433 pathway is an important signaling pathway for @entity72049 expression and that these proteins may play a critical role in eliciting @entity8932 -mediated immune and inflammatory response. This article is protected by copyright. All rights reserved.

title: Regulation of @entity72049 Expression by @entity16404 - XXXX - @entity10433 Signaling Pathway.

answer: @entity8837 :: (26417;26413,Gene) :: ['ERK1/2']


abstract: CONCLUSION: This method is an easy, non-expensive, and effective technique in bilateral @entity3746 to improve glottic airway and clinical performance. OBJECTIVE: To evaluate the effectiveness of 'suture arytenoid laterofixation' surgery in bilateral @entity3746 . MATERIALS AND METHODS: A retrospective analysis of @entity1 ' medical history undergoing 'suture arytenoid laterofixation' surgery for bilateral @entity3746 . This technique was applied under general anesthesia with both microlaryngoscopy and video-monitoring. Two 16 g needles and one 1/0 nylon thread were used for the procedure with 1 cm skin incision; no tracheotomy or tissue excision was required. Pre-post-operative photographs of the glottic region were taken from the endoscopic records, and the areas of rima glottis openings were calculated with the Image-J programme. RESULTS: Forty-seven @entity1 were analyzed. The mean pre-post-operative rima glottis areas were 1.11    0.56 and 2.24    0.93 mm(2), respectively (p < 0.001). Five @entity1 with previous tracheotomy were decannulated within a few days after the operation. In three @entity1 , mild complications developed in the early post-operative period (two @entity4 , one @entity1410 ). Tracheotomy was performed to only one pregnant @entity1 in the post-operative first day. None of the @entity1 had granulation formation or @entity5862 .

title: Glottic airway gain after 'suture arytenoid laterofixation' in bilateral XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity4 :: ('MESH:D004487', 'Disease') :: ['laryngeal edemas']

entities_list: @entity1410 :: ('MESH:D006406', 'Disease') :: ['submucosal hematoma']

entities_list: @entity3746 :: ('MESH:D014826', 'Disease') :: ['vocal cord paralysis']

answer: @entity3746 :: (MESH:D014826,Disease) :: ['vocal cord paralysis']


abstract: BACKGROUND: The current standard therapy for @entity1 with @entity1892 ( @entity1892 ) is rituximab plus @entity786 , @entity632 , @entity1891 and @entity229 (RCHOP). The role of radiotherapy (RT) after complete response (CR) to RCHOP in @entity1 with @entity1892 remains unclear. This systematic review with a meta-analysis is an attempt to evaluate this role. METHODS: Studies that evaluated RT versus no-RT after CR to RCHOP for @entity1892 @entity1 were searched in databases. Hazard ratios (HR) with their respective 95% confidence intervals (CI) were calculated using a random-effects model. RESULTS: A total of 4 qualified retrospective studies (633 @entity1 ) were included in this review. The results suggested that RT improved overall survival (OS; HR 0.33, 95% CI 0.14-0.77) and progression-free/event-free survival (PFS/EFS; HR 0.24, 95% CI 0.11-0.50) in all @entity1 compared with no-RT. In a subgroup analysis of @entity1 with stage III-IV @entity1892 , RT improved PFS/EFS (HR 0.19, 95% CI 0.07-0.51) and local control (HR 0.12, 95% CI 0.03-0.44), with a trend of improving OS (HR 0.35, 95% CI 0.12-1.05). CONCLUSION: Consolidation RT could significantly improve outcomes of @entity1892 @entity1 who achieved a CR to RCHOP. However, the significance of these results was limited by these retrospective data. Further investigation of the role of consolidation RT in the rituximab era is needed.    2015 S. Karger AG, Basel.

title: The Role of Consolidative Radiotherapy after a Complete Response to Chemotherapy in the Treatment of Diffuse Large XXXX in the Rituximab Era: Results from a Systematic Review with a Meta-Analysis.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity632 :: ('MESH:D004317', 'Chemical') :: ['doxorubicin']

entities_list: @entity229 :: ('MESH:D011241', 'Chemical') :: ['prednisone']

entities_list: @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide']

entities_list: @entity1892 :: ('MESH:D016393', 'Disease') :: ['DLBCL', 'diffuse large B-cell lymphoma']

entities_list: @entity1891 :: ('MESH:D014750', 'Chemical') :: ['vincristine']

answer: @entity1892 :: (MESH:D016393,Disease) :: ['B-Cell Lymphoma']


abstract: OBJECTIVES: In older @entity1 , @entity79 ( @entity79 ) diminishes with age, increasing susceptibility to @entity2249 . Evidence has emerged that @entity1 who should have dual x-ray absorptiometry scans to evaluate their bone health are not doing so. Because computed tomography (CT) attenuation has now been correlated with @entity79 thresholds relating to @entity170 , virtually any existing CT scan that includes the L1 vertebra can be used to assess @entity79 . This study evaluates the utility of CT attenuation in characterizing @entity79 in @entity1 after @entity2249 . METHODS: The electronic medical records of adults who presented to a level I @entity130 center with @entity173 were evaluated for eligibility. Those with a CT scan of the abdomen or other CT scan with a complete view of the L1 vertebra were included. To measure attenuation, a region of interest was selected to include the body of the L1 vertebra in the axial plane and exclude the cortices and posterior venous complex. RESULTS: Of the 589 @entity1 reviewed, 217 met inclusion criteria; 112 were aged 18 to 64, while 105 were >= 65. Eight (7.1%) @entity1 in the younger cohort had a mean CT attenuation below the 110-HU threshold set for 90% specificity, whereas 31 (29.5%) @entity1 in the older cohort had a mean CT attenuation below this threshold. Using the 160-HU threshold set for 90% sensitivity, 39 (34.8%) @entity1 of the younger cohort and 74 (70%) @entity1 of the older cohort were osteoporotic; all differences in CT attenuation by age were strongly significant (P < .0001). CONCLUSIONS: A significantly larger proportion of older @entity1 with @entity173 had @entity170 , helping validate the utility of CT attenuation in this context. In addition, a large proportion of these @entity1 already had these images available, thus potentially helping limit cost and unnecessary medical investigations.

title: Assessing Bone Mineral Density Following Acute XXXX : The Role of Computed Tomography Attenuation.

entities_list: @entity2249 :: ('MESH:D005265', 'Disease') :: ['femoral neck fractures']

entities_list: @entity170 :: ('MESH:D010024', 'Disease') :: ['osteoporosis']

entities_list: @entity79 :: ('MESH:D001847', 'Disease') :: ['bone mineral density', 'BMD']

entities_list: @entity173 :: ('MESH:D006620', 'Disease') :: ['hip fractures']

answer: @entity173 :: (MESH:D006620,Disease) :: ['Hip Fractures']


abstract: BACKGROUND: Leukocyte-poor platelet-rich plasma (LP- @entity3669 ) is hypothesized to be more suitable for intra-articular injection than leukocyte-rich @entity3669 (LR- @entity3669 ) in the treatment of @entity626 . PURPOSE: To compare clinical outcomes and rates of adverse reactions between LP- @entity3669 and LR- @entity3669 for this application. STUDY DESIGN: Meta-analysis. METHODS: The MEDLINE, EMBASE, and Cochrane databases were reviewed. The primary outcome was the incidence of local adverse reactions. Secondary outcomes were the changes in International Knee Documentation Committee (IKDC) subjective score and Western Ontario and McMaster Universities @entity571 Index (WOMAC) score between baseline and final follow-up measurements. A Bayesian network meta-analysis was performed, with a post hoc meta-regression to correct for baseline differences in WOMAC scores. Treatment rankings were based on surface under the cumulative ranking (SUCRA) probabilities. RESULTS: Included in the analysis were 6 randomized controlled trials (evidence level 1) and 3 prospective comparative studies (evidence level 2) with a total of 1055 @entity1 . Injection of LP- @entity3669 resulted in significantly better WOMAC scores than did injection of hyaluronic acid (mean difference, -21.14; 95% CI, -39.63 to -2.65) or placebo (mean difference, -17.84; 95% CI, -34.95 to -0.73). No such difference was observed with LR- @entity3669 (mean difference, -14.28; 95% CI, -44.80 to 16.25). All treatment groups resulted in equivalent IKDC subjective scores. The SUCRA analysis showed that LP- @entity3669 was the highest ranked treatment for both measures of clinical efficacy (WOMAC and IKDC). Finally, @entity3669 injections resulted in a higher incidence of adverse reactions than hyaluronic acid (odds ratio, 5.63; 95% CI, 1.38-22.90), but there was no difference between LR- @entity3669 and LP- @entity3669 (odds ratio, 0.78; 95% CI, 0.05-11.93). These reactions were nearly always local swelling and @entity158 , with a single study reporting medical side effects including @entity1163 , @entity1296 , @entity10 , @entity3621 , and @entity591 (17/1055 total @entity1 ). CONCLUSION: LP- @entity3669 results in improved functional outcome scores compared with hyaluronic acid and placebo when used for treatment of @entity626 . LP- @entity3669 and LR- @entity3669 have similar safety profiles, although both induce more transient reactions than does hyaluronic acid. Adverse reactions to @entity3669 may not be directly related to leukocyte concentration.

title: Effect of Leukocyte Concentration on the Efficacy of Platelet-Rich Plasma in the Treatment of Knee XXXX .

entities_list: @entity626 :: ('MESH:D020370', 'Disease') :: ['knee osteoarthritis']

entities_list: @entity571 :: ('MESH:D010003', 'Disease') :: ['Osteoarthritis']

entities_list: @entity591 :: ('MESH:D013610', 'Disease') :: ['tachycardia']

entities_list: @entity3621 :: ('MESH:D005756', 'Disease') :: ['gastritis']

entities_list: @entity1296 :: ('MESH:D004244', 'Disease') :: ['dizziness']

entities_list: @entity10 :: ('MESH:D006261', 'Disease') :: ['headache']

answer: @entity571 :: (MESH:D010003,Disease) :: ['Osteoarthritis']


abstract: OBJECTIVES: The aim of the present study was to assess differences and correlations between the hippocampal volumes (HCVs), serum @entity4150 ( @entity4150 ), and @entity2252 ( @entity2252 ) levels in adolescents with @entity162 ( @entity162 ) compared to healthy controls. METHODS: Using structural magnetic resonance imaging, we compared HCVs of 30 @entity1 with euthymic @entity162 who were already enrolled in a naturalistic clinical follow-up. For comparison, we enrolled 23 healthy controls between the ages of 13 and 19. The boundaries of the hippocampus were outlined manually. The @entity2252 and @entity4150 serum levels were measured with the sandwich ELISA. RESULTS: The groups did not differ in the right or left HCVs or in the @entity4150 or @entity2252 serum levels. However, negative correlations were found between the right HCVs and the duration of the disorder and medication and positive correlations were found between the duration of the medications and the @entity4150 and @entity2252 levels in the @entity1 group. Additionally, positive correlations were found between the follow-up period and left normalized HCVs in both the @entity162 and @entity1091 -treated groups. CONCLUSIONS: The right HCVs may vary with illness duration and the medication used to treat @entity162 ; @entity4150 and @entity2252 levels may be affected by long-term usage. Further research is needed to determine whether these variables and their structural correlates are associated with clinical or functional differences between adolescents with @entity162 and healthy controls.    2015 S. Karger AG, Basel.

title: Decreased right hippocampal volumes and neuroprogression markers in adolescents with XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity162 :: ('MESH:D001714', 'Disease') :: ['bipolar disorder', 'BP']

entities_list: @entity4150 :: ('4803', 'Gene') :: ['nerve growth factor', 'NGF']

entities_list: @entity2252 :: ('627', 'Gene') :: ['brain-derived neurotrophic factor', 'BDNF']

answer: @entity162 :: (MESH:D001714,Disease) :: ['bipolar disorder']


abstract: BACKGROUND: The use of @entity4944 -type stimulants (ATS) places a large burden on health services. OBJECTIVE: The aim was to evaluate the effectiveness of a self-guided Web-based intervention ("breakingtheice") for ATS users over 6 months via a free-to-access site. METHODS: We conducted a randomized trial comparing a waitlist control with a fully automated intervention containing 3 modules derived from cognitive behavioral therapy and motivation enhancement. The main outcome was self-reported ATS use in the past 3 months assessed at 3- and 6-month follow-ups using the @entity285 , Smoking, and Substance Involvement Screening Test (ASSIST). Secondary outcomes were help-seeking intentions (general help-seeking questionnaire), actual help seeking (actual help-seeking questionnaire), @entity458 (Kessler 10), polydrug use (ASSIST), quality of life (European Health Interview Survey), days out of role, and readiness to change. Follow-up data were evaluated using an intention-to-treat (ITT) analysis with a group by time interaction. RESULTS: We randomized 160 @entity1 (intervention: n=81; control: n=79). At 6 months, 38 of 81 (47%) intervention and 41 of 79 (52%) control @entity1 provided data. ATS scores significantly declined for both groups, but the interaction effect was not significant. There were significant ITT time by group interactions for actual help seeking (rate ratio [RR] 2.16; d=0.45) and help-seeking intentions (RR 1.17; d=0.32), with help seeking increasing for the intervention group and declining for the control group. There were also significant interactions for days completely (RR 0.50) and partially (RR 0.74) out of role favoring the intervention group. However, 37% (30/81) of the intervention group did not complete even 1 module. CONCLUSIONS: This self-guided Web-based intervention encouraged help seeking associated with ATS use and reduced days out of role, but it did not reduce ATS use. Thus, this program provides a means of engaging with some sections of a difficult-to-reach group to encourage treatment, but a substantial minority remained disengaged. TRIAL REGISTRATION: Australian and New Zealand Clinical Trials Registry: ACTRN12611000947909; https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=343307 (Archived by WebCite at http://www.webcitation.org/6Y0PGGp8q).

title: Six-month outcomes of a Web-based intervention for users of XXXX -type stimulants: randomized controlled trial.

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'people']

entities_list: @entity4944 :: ('MESH:D000661', 'Chemical') :: ['amphetamine']

entities_list: @entity458 :: ('MESH:D020018', 'Disease') :: ['psychological distress']

answer: @entity4944 :: (MESH:D000661,Chemical) :: ['amphetamine']


abstract: BACKGROUND AND OBJECTIVE: To clinically correlate and evaluate the screening and treatment patterns of @entity989 of @entity3465 by a single physician at a tertiary care center between 2002 and 2012. @entity1 AND METHODS: A group of 10,924 newborns screened for @entity6109 between 2002 and 2012 were retrospectively analyzed in a consecutive case series. Records of the neonatal intensive care unit (NICU) at Jackson Memorial Hospital/Bascom Palmer Eye Institute were reviewed to identify @entity1 clinically diagnosed with @entity989 of @entity3465 who underwent treatment. RESULTS: Laser photocoagulation was used to treat 231 of 10,924 (2.1%). Of these 231 @entity1 , 176 (76.2%) were included in the study (55 @entity1 were excluded because they were referred from outside institutions for advanced @entity6109 ). Of the 176 treated @entity1 , 89 (50.6%) were male and 87 (49.4%) were female. The average birth weight was 687.3 g. The mean gestational age was 24.8 weeks. The mean time between birth and treatment was 3 months. Of the 176 @entity1 , 31 required re-treatment with laser photocoagulation. The rates of treatment and retreatment significantly declined with the experience of the treating physician ( P < .01). @entity1713 occurred in two of 176 @entity1 (1.1%). CONCLUSION: Experience is essential in delivering optimal care in a complex disease such as @entity6109 . Between 2002 and 2012, the rate of treatment and retreatment significantly decreased. Possible reasons include improvements in neonatal care, but it is more likely that the rate of treatment and re-treatment is inversely proportional to the ophthalmologist's experience with and comfort in managing @entity6109 .

title: Changing Treatment Patterns of XXXX at a Tertiary Medical Center Between 2002 and 2012.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS', 'infants']

entities_list: @entity989 :: ('MESH:D012164', 'Disease') :: ['retinopathy']

entities_list: @entity3465 :: ('MESH:C536271', 'Disease') :: ['prematurity']

entities_list: @entity1713 :: ('MESH:D012163', 'Disease') :: ['Retinal detachment']

answer: @entity6109 :: (MESH:C536382,Disease) :: ['ROP']


abstract: PURPOSE: @entity5787 ( @entity5787 ) autoantibodies (TPOAb) seem to be protective for @entity1 with @entity0 ( @entity0 ). Thyroid and breast tissues both express the @entity22598 symporter ( @entity49507 ), similarly both have a peroxidase activity, @entity5787 and lactoperoxidase ( @entity38415 ) respectively. We hypothesize a common immune response to a thyroid/breast shared antigen suggesting three putative mechanisms: (1) TPOAb react to both @entity5787 and @entity38415 , (2) @entity5787 could be expressed in @entity0 and (3) @entity1 with TPOAb could have autoantibodies to @entity49507 (NISAb). Previous studies excluded NISAb that block @entity49507 activity in sera of @entity1 with @entity1669 ( @entity1669 ) and/or @entity0 . This study investigates neutral NISAb (binding without affecting function). METHODS: Clones of @entity435 cells stably expressing @entity1 @entity49507 ( @entity49507 ; @entity435 - @entity49507 ) were isolated following transfection of @entity49507 in pcDNA3 vector. Expression of @entity49507 mRNA and surface protein was confirmed by PCR and flow cytometry respectively using a @entity49507 -mouse-monoclonal-antibody. @entity435 - @entity49507 and controls transfected with the empty pcDNA3 vector ( @entity435 -Empty) were incubated with 42 heat-inactivated @entity1 sera followed by an anti-human-IgG- @entity21112 -conjugate: 12 with @entity0 , 11 with @entity1669 , 10 with both @entity0 and @entity1669 and 9 with non-autoimmune @entity1374 . The Kolmogorov-Smirnov Test was used to compare the fluorescence intensity obtained with @entity435 - @entity49507 and @entity435 -Empty, using sera from six young males as a negative control population. RESULTS: None of the 42 sera were positive for NISAb. CONCLUSIONS: NISAb are rare and @entity49507 is unlikely to be a common thyroid/ @entity0 shared antigen. We have recently demonstrated @entity5787 expression in @entity0 tissue and are currently investigating TPOAb cross-reactivity with @entity5787 / @entity38415 .

title: The XXXX symporter is unlikely to be a thyroid/breast shared antigen.

entities_list: @entity1 :: ('9606', 'Species') :: ['human', 'patients']

entities_list: @entity22598 :: ('MESH:D012974', 'Chemical') :: ['sodium iodide']

entities_list: @entity5787 :: ('7173', 'Gene') :: ['TPO', 'Anti-thyroid peroxidase']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer', 'BC']

entities_list: @entity1669 :: ('MESH:D013967', 'Disease') :: ['thyroid autoimmunity', 'TA']

entities_list: @entity1374 :: ('MESH:D013959', 'Disease') :: ['thyroid diseases']

answer: @entity22598 :: (MESH:D012974,Chemical) :: ['sodium iodide']


abstract: Pregnant @entity35 were injected with 0, 6 or 10 mg/kg of @entity3319 on Days 6-9 of gestation. Dams given the 10 mg/kg dose failed to deliver young or produced stillborn. External morphology was normal for @entity35 given either the 0 or 6 mg/kg dose. Whole brains were examined from male and female @entity35 , 21 or 90 days old. External brain dimensions were measured with calipers. Brains were sectioned at three criterion locations. A microprojector was used to project brain sections in order to measure intrastructural distances. Sections were examined with a light microscope to look for abnormalities. Various expected age-related changes were noted showing the sensitivity of the anatomical methods. @entity5165 produced @entity1276 , decreased thickness of cerebral cortex in the parietal section and increased thickness of hippocampus in the occipital section. With these exceptions, the brains of @entity349 -treated @entity35 showed normal development.

title: Effects of the high XXXX dose used in the collaborative behavioral teratology study on brain anatomy.

entities_list: @entity1276 :: ('MESH:D006849', 'Disease') :: ['hydrocephalus']

entities_list: @entity349 :: ('MESH:D008628', 'Chemical') :: ['mercury']

entities_list: @entity3319 :: ('MESH:C004925', 'Chemical') :: ['methylmercuric chloride']

entities_list: @entity5165 :: ('CHEBI:30785', 'Chemical') :: ['Methylmercury']

answer: @entity5165 :: (CHEBI:30785,Chemical) :: ['methylmercury']


abstract: OBJECTIVE: To describe the cross-cultural adaptation of the Affective Reactivity Index (ARI) to Brazilian Portuguese and to investigate preliminary psychometric properties of the adapted version. METHODS: Cross-cultural adaptation was based on the investigation of the theoretical and operational equivalences of the original ARI in the Brazilian context, followed by a process of translation, back-translation, and review by a committee of experts. Data analysis was carried out in a community sample of 133 schoolchildren aged 8 to 17 years to investigate the following characteristics of the ARI: 1) factor structure; 2) internal consistency; 3) construct validity comparing differential relationships between @entity146 and @entity148 ; and 4) item response theory (IRT) parameters. RESULTS: A final Brazilian Portuguese version of the instrument was defined and is presented. Internal consistency was good, and our analysis supported the original single-factor structure of the ARI. Correlations of the ARI with distress-related @entity148 dimensions were higher than with phobic-related @entity148 dimensions, supporting its construct validity. In addition, higher ARI scores were associated with higher @entity146 . IRT analysis underscored frequency of loss of temper as essential to inform about pathological states of @entity146 . CONCLUSION: The Brazilian Portuguese version of the ARI seems to be very similar to the original instrument in terms of conceptual, item, semantic, and operational equivalence. Our preliminary analysis replicates and extends previous evidence confirming promising psychometric properties for the ARI.

title: Cross-cultural adaptation and preliminary psychometric properties of the Affective Reactivity Index in Brazilian Youth: implications for DSM-5 measured XXXX .

entities_list: @entity148 :: ('MESH:D001008', 'Disease') :: ['anxiety', 'anxiety dimensions and impairment']

entities_list: @entity146 :: ('MESH:D001523', 'Disease') :: ['irritability-related impairment', 'irritability']

answer: @entity146 :: (MESH:D001523,Disease) :: ['irritability']


abstract: @entity579 grain yield is predicted to decrease in the future because of an increase in tropospheric ozone concentration. However, the underlying mechanisms are unclear. Here, we investigated the responses to ozone of two @entity579 ( @entity579 .) cultivars, Sasanishiki and Habataki. Sasanishiki showed ozone-induced @entity130 , but no grain yield loss. By contrast, Habataki showed grain yield loss with minimal @entity130 . A QTL associated with grain yield loss caused by ozone was identified in Sasanishiki/Habataki chromosome segment substitution lines and included the ABERRANT PANICLE ORGANIZATION 1 (APO1) gene. The Habataki allele of the APO1 locus in a near-isogenic line also resulted in grain yield loss upon ozone exposure, suggesting APO1 involvement in ozone-induced yield loss. Only a few differences in the APO1 amino acid sequences were detected between the cultivars, but the APO1 transcript level was oppositely regulated by ozone exposure: i.e., it increased in Sasanishiki and decreased in Habataki. Interestingly, the levels of some phytohormones (jasmonic acid, jasmonoyl-L-isoleucine, and abscisic acid) known to be involved in attenuation of ozone-induced @entity130 tended to decrease in Sasanishiki but to increase in Habataki upon ozone exposure. These data indicate that ozone-induced grain yield loss in Habataki is caused by a reduction in the APO1 transcript level through an increase in the levels of phytohormones that reduce leaf damage.

title: Ozone-Induced XXXX Grain Yield Loss Is Triggered via a Change in Panicle Morphology That Is Controlled by ABERRANT PANICLE ORGANIZATION 1 Gene.

entities_list: @entity579 :: ('4530', 'Species') :: ['Oryza Sativa L', 'rice', 'Rice']

entities_list: @entity130 :: ('MESH:D014947', 'Disease') :: ['leaf injury']

answer: @entity579 :: (4530,Species) :: ['Rice']


abstract: UNASSIGNED: The aim of this study was to investigate the prognosis associated with @entity5036 ( @entity5036 ) depending on location, time of appearance, and duration in @entity1 with @entity583 ( @entity583 ). From January 1998 to January 2008, we recruited 5,570 @entity1 with @entity583 . Thirty-day and 7-year all-cause mortality, according to @entity5036 location, time of appearance, and duration were analyzed by multivariable analyses. @entity5036 was present in 964 @entity1 (17.3%); @entity714 ( @entity18151 ) 10.6% and @entity18151 ( @entity18151 ) 6.7%. Overall mortality rate at 30 days was 13.2% (n  = 738) and 7 years was 6.34 deaths per 100 @entity1 -year. Both @entity18151 and @entity18151 were more frequently previous, 42.9% and 58.8%. Compared with non- @entity5036 , all @entity5036 groups showed higher prevalence of co-morbidities, especially rates of @entity6 (49.0% vs 34.3%, p <0.001) and more often @entity712 during hospitalization (54.5% vs 26.6%, p <0.001). Compared with @entity18151 , @entity1 with @entity18151 had a higher prevalence of co-morbidities and a higher mortality, especially the new @entity5036 , 30 days: 52.5% versus 31.6% and 7 years (incident rate): 27.2 versus 13.3 per 100 @entity1 -year. New transient @entity5036 had lower @entity712 on admission (42.6% vs 58.3%, p  = 0.008) and 30-day mortality (20.3% vs 69.6%, p <0.001) compared with permanent in both locations. New permanent @entity18151 was independently associated with 30-day (hazard ratio [HR] 2.01, 95% confidence interval [CI] 1.45 to 2.79) and 7-year mortality (HR 3.12, 95% CI 2.38 to 4.09). New-permanent @entity18151 was independently associated with 30-day (HR 2.15, 95% CI 1.47 to 3.15) and 7-year mortality (HR 2.91, 95% CI 2.08 to 4.08). In conclusion, in @entity1 with @entity583 , the appearance of a new @entity5036 was independently associated with a higher 30-day and 7-year all-cause mortality.

title: Relation of New Permanent Right or Left Bundle Branch Block on Short- and Long-Term Mortality in Acute XXXX Bundle Branch Block and  @entity583 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity712 :: ('MESH:D006333', 'Disease') :: ['heart failure']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes']

entities_list: @entity714 :: ('MESH:D002037', 'Disease') :: ['right BBB']

entities_list: @entity5036 :: ('OMIM:113900', 'Disease') :: ['bundle branch block', 'BBB']

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['acute MI', 'myocardial infarction', 'MI']

answer: @entity583 :: (MESH:D009203,Disease) :: ['Myocardial Infarction']


abstract: UNASSIGNED: The aim of this study was to investigate the prognosis associated with @entity5036 ( @entity5036 ) depending on location, time of appearance, and duration in @entity1 with @entity583 ( @entity583 ). From January 1998 to January 2008, we recruited 5,570 @entity1 with @entity583 . Thirty-day and 7-year all-cause mortality, according to @entity5036 location, time of appearance, and duration were analyzed by multivariable analyses. @entity5036 was present in 964 @entity1 (17.3%); @entity714 ( @entity18151 ) 10.6% and @entity18151 ( @entity18151 ) 6.7%. Overall mortality rate at 30 days was 13.2% (n  = 738) and 7 years was 6.34 deaths per 100 @entity1 -year. Both @entity18151 and @entity18151 were more frequently previous, 42.9% and 58.8%. Compared with non- @entity5036 , all @entity5036 groups showed higher prevalence of co-morbidities, especially rates of @entity6 (49.0% vs 34.3%, p <0.001) and more often @entity712 during hospitalization (54.5% vs 26.6%, p <0.001). Compared with @entity18151 , @entity1 with @entity18151 had a higher prevalence of co-morbidities and a higher mortality, especially the new @entity5036 , 30 days: 52.5% versus 31.6% and 7 years (incident rate): 27.2 versus 13.3 per 100 @entity1 -year. New transient @entity5036 had lower @entity712 on admission (42.6% vs 58.3%, p  = 0.008) and 30-day mortality (20.3% vs 69.6%, p <0.001) compared with permanent in both locations. New permanent @entity18151 was independently associated with 30-day (hazard ratio [HR] 2.01, 95% confidence interval [CI] 1.45 to 2.79) and 7-year mortality (HR 3.12, 95% CI 2.38 to 4.09). New-permanent @entity18151 was independently associated with 30-day (HR 2.15, 95% CI 1.47 to 3.15) and 7-year mortality (HR 2.91, 95% CI 2.08 to 4.08). In conclusion, in @entity1 with @entity583 , the appearance of a new @entity5036 was independently associated with a higher 30-day and 7-year all-cause mortality.

title: Relation of New Permanent Right or Left Bundle Branch Block on Short- and Long-Term Mortality in Acute @entity583 Bundle Branch Block and  XXXX .

answer: @entity583 :: (MESH:D009203,Disease) :: ['Myocardial  Infarction']


abstract: UNASSIGNED: @entity233 flocks have experienced @entity233 @entity1681 sporadically in the United States since the 1990s. Twenty-four field isolates of @entity45418 (TCoV) from multiple states in the United States were recovered from 1994 to 2010 to determine the genetic relationships among them. The entire spike (S) gene of each TCoV isolate was amplified and sequenced. Pairwise comparisons were performed using the Clustal W program, revealing 90.0  % to 98.4  % sequence identity in the full-length S protein, 77.6  % to 96.6  % in the @entity1472 terminus of the S1 subunit (containing one hypervariable region in S1a), and 92.1  % to 99.3  % in the S2 subunit at the deduced @entity3689 sequence level. The conserved motifs, including two cleavage recognition sequences of the S protein, two heptad repeats, the transmembrane domain, and the Golgi retention signal were identified in all TCoV isolates. Phylogenetic analysis based on the full-length S gene was used to distinguish North American TCoV isolates from French TCoV isolates. Among the North American TCoV isolates, three distinct genetic groups with 100  % bootstrap support were observed. North Carolina isolates formed group I, Texas isolates formed group II, and Minnesota isolates formed Group III. The S genes of 24 TCoV isolates from the United States remained conserved because they contained predominantly synonymous substitutions. The findings of the present study suggest endemic circulation of distinct TCoV genotypes in different geographic locations.

title: Genotyping of XXXX field isolates from various geographic locations in the Unites States based on the spike gene.

entities_list: @entity45418 :: ('11152', 'Species') :: ['turkey coronavirus']

entities_list: @entity1681 :: ('MESH:D004751', 'Disease') :: ['coronaviral enteritis']

answer: @entity45418 :: (11152,Species) :: ['turkey coronavirus']


abstract: UNASSIGNED: The vertebrate gene family for neuropeptide Y ( @entity7766 ) receptors expanded by duplication of the chromosome carrying the ancestral Y1-Y2-Y5 gene triplet. After loss of some duplicates, the ancestral jawed vertebrate had seven receptor subtypes forming the Y1 (including Y1, Y4, Y6, Y8), Y2 (including Y2, Y7) and Y5 (only Y5) subfamilies. Lampreys are considered to have experienced the same chromosome duplications as gnathostomes and should also be expected to have multiple receptor genes. However, previously only a Y4-like and a Y5 receptor have been cloned and characterized. Here we report the cloning and characterization of two additional receptors from the @entity26962 @entity26962 . Sequence phylogeny alone could not with certainty assign their identity, but based on synteny comparisons of @entity42384 and the Arctic lamprey, Lethenteron camtschaticum, with jawed vertebrates, the two receptors most likely are Y1 and Y2. Both receptors were expressed in @entity1 HEK293 cells and @entity19260 assays were performed to determine the response to the three native lamprey peptides @entity7766 , @entity1942 and PMY. The three peptides have similar potencies in the nanomolar range for Y1. No obvious response to the three peptides was detected for Y2. Synteny analysis supports identification of the previously cloned receptor as Y4. No additional @entity7766 receptor genes could be identified in the presently available lamprey genome assemblies. Thus, four @entity7766 -family receptors have been identified in lampreys, orthologs of the same subtypes as in @entity1 ( @entity72050 ), whereas many other vertebrate lineages have retained additional ancestral subtypes.

title: Neuropeptide Y family receptors Y1 and Y2 from XXXX , @entity26962 .

entities_list: @entity1 :: ('9606', 'Species') :: ['humans', 'human']

entities_list: @entity26962 :: ('7757', 'Species') :: ['sea lamprey', 'Petromyzon marinus']

entities_list: @entity19260 :: ('CHEBI:24846', 'Chemical') :: ['inositol phosphate']

answer: @entity26962 :: (7757,Species) :: ['sea lamprey']


abstract: UNASSIGNED: The vertebrate gene family for neuropeptide Y ( @entity7766 ) receptors expanded by duplication of the chromosome carrying the ancestral Y1-Y2-Y5 gene triplet. After loss of some duplicates, the ancestral jawed vertebrate had seven receptor subtypes forming the Y1 (including Y1, Y4, Y6, Y8), Y2 (including Y2, Y7) and Y5 (only Y5) subfamilies. Lampreys are considered to have experienced the same chromosome duplications as gnathostomes and should also be expected to have multiple receptor genes. However, previously only a Y4-like and a Y5 receptor have been cloned and characterized. Here we report the cloning and characterization of two additional receptors from the @entity26962 @entity26962 . Sequence phylogeny alone could not with certainty assign their identity, but based on synteny comparisons of @entity42384 and the Arctic lamprey, Lethenteron camtschaticum, with jawed vertebrates, the two receptors most likely are Y1 and Y2. Both receptors were expressed in @entity1 HEK293 cells and @entity19260 assays were performed to determine the response to the three native lamprey peptides @entity7766 , @entity1942 and PMY. The three peptides have similar potencies in the nanomolar range for Y1. No obvious response to the three peptides was detected for Y2. Synteny analysis supports identification of the previously cloned receptor as Y4. No additional @entity7766 receptor genes could be identified in the presently available lamprey genome assemblies. Thus, four @entity7766 -family receptors have been identified in lampreys, orthologs of the same subtypes as in @entity1 ( @entity72050 ), whereas many other vertebrate lineages have retained additional ancestral subtypes.

title: Neuropeptide Y family receptors Y1 and Y2 from @entity26962 , XXXX .

answer: @entity26962 :: (7757,Species) :: ['Petromyzon marinus']


abstract: UNASSIGNED: The objective of this study was to determine the relationship between citrullinated proteins in synovial tissue with peripheral anti-citrullinated peptides autoantibodies (ACPA) and peptidylarginine deiminase (PADI) @entity30445 , @entity72051 , and @entity22403 messenger RNA (mRNA) expressions in synovial tissue and fibroblast-like synoviocytes in @entity309 ( @entity309 ) @entity1 . Eleven @entity309 and 12 @entity571 ( @entity571 ) @entity1 who underwent knee replacement surgery were studied. We detected citrullinated proteins in synovial tissue homogenates by western blot and serum ACPA by ELISA to anti-cyclic citrullinated peptide (anti- @entity5810 ) antibodies, and @entity30445 , @entity72051 , and @entity22403 mRNA expressions in synovial tissue and in fibroblast-like synoviocytes. @entity1 with high amount of citrullinated proteins in synovial tissue (3 out of 7) have high levels of anti- @entity5810 in serum. However, in the remaining 4 @entity1 , the amount of synovial citrullinated proteins was minimal and their sera showed low levels of anti- @entity5810 antibodies. Furthermore, we observed an increase in @entity30445 mRNA expression in @entity309 synovial tissue compared with @entity571 @entity1 (p   =   0.02). We detected @entity72051 mRNA in the synovial tissue of @entity309 @entity1 , but not in the tissue of @entity571 @entity1 . Even though fibroblast-type synoviocytes in @entity309 are not the main source of PADs in the synovial tissue, they express @entity30445 mRNA moderately, @entity22403 mRNA weakly, while there is no detectable expression of @entity72051 mRNA. In conclusion, we found a variety of citrullinated proteins in the synovial tissue of @entity309 @entity1 and the amount of such proteins is related to serum concentration of anti- @entity5810 antibodies. We identified the presence of  @entity72051 mRNA expression in synovial tissue and @entity30445 and @entity22403 mRNA expressions in fibroblast-like synoviocytes from @entity1 with @entity309 .

title: The amount of citrullinated proteins in synovial tissue is related to serum anti-cyclic citrullinated peptide (anti- XXXX ) antibody levels.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity571 :: ('MESH:D010003', 'Disease') :: ['OA', 'osteoarthritis']

entities_list: @entity309 :: ('MESH:D001172', 'Disease') :: ['rheumatoid arthritis', 'RA']

answer: @entity5810 :: (CHEBI:35889,Chemical) :: ['CCP']


abstract: BACKGROUND AND AIMS: Classical features of @entity775 ( @entity19180 ) may be altered during the abrupt onset of the disease. @entity228 therapy can be life-saving, but its use in the fulminant presentation of @entity19180 ( @entity19180 ) remains controversial. We aimed to assess the clinical features of @entity1 with @entity19180 and to describe the role of corticosteroids in this population. @entity1 AND METHODS: We retrospectively analyzed 154 adult @entity1 with @entity879 who were admitted to six liver transplantation (LT) programs. The @entity19180 simplified criteria were used to identify @entity1 with @entity19180 . RESULTS: We identified 40 (26%) @entity1 with @entity19180 . Compared with other etiologies, @entity1 with @entity19180 presented a longer interval from @entity1087 to @entity75 (26 vs. 16 days, P=0.02) and a lower @entity3851 ( @entity3851 ) score on admission (29 vs. 33, P=0.002). Overall, 25 (62%) @entity1 with @entity19180 underwent LT, eight (20%) @entity1 survived, and seven (18%) died without LT. Seventeen @entity1 received corticosteroids therapy, of whom seven (41%) survived without LT. Among the treated @entity1 , higher @entity3851 score and @entity75 grade of 3 or more were associated significantly with @entity177 . CONCLUSION: @entity1 with @entity19180 have a more indolent presentation compared with the non- @entity19180 population. Altogether, only eight (20%) @entity1 presenting with @entity19180 survived without LT. A subset of @entity1 with @entity19180 and an initial @entity3851 score less than 27 and low-grade hepatic @entity75 might benefit from administration of corticosteroids.

title: Fulminant presentation of XXXX : clinical features and early predictors of corticosteroid treatment failure.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'PATIENTS']

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['encephalopathy']

entities_list: @entity879 :: ('MESH:D017114', 'Disease') :: ['fulminant hepatic failure']

entities_list: @entity228 :: ('CHEBI:50858', 'Chemical') :: ['Corticosteroid']

entities_list: @entity177 :: ('MESH:D051437', 'Disease') :: ['corticosteroid failure']

entities_list: @entity3851 :: ('MESH:D058625', 'Disease') :: ['MELD', 'Model for End-Stage Liver Disease']

entities_list: @entity775 :: ('MESH:D019693', 'Disease') :: ['autoimmune hepatitis']

answer: @entity775 :: (MESH:D019693,Disease) :: ['autoimmune hepatitis']


abstract: AIMS: The study aims to develop a novel multistep chromatographic purification process for @entity1 enterovirus71 virus-like particles (VLPs) produced from insect cells (Sf9) infected with recombinant baculovirus. METHODS AND RESULTS: Sf9 cells were maintained in the Wave Bioreactor system 20/50, and harvested when the viability decreased to 75% after infected with Bac-P1-3CD at the multiplicity of @entity281 (MOI) of 1. After sonication and centrifugation, EV71 VLPs were purified with Capto(   ) Core 700, Capto(   ) adhere and Capto(   ) @entity9010 . The purity was then determined by SDS-PAGE, Western blotting and high-performance liquid chromatography (HPLC), while the diameter of purified EV71 VLPs was analysed by Dynamic Light Scattering (DLS) and Transmission electron microscopy (TEM). Immunization of BALB/c mice and serum collection were performed after contamination analysis, and neutralization antibodies were then analysed by pseudovirus-based microneutralization assay. Results showed that these purified EV71 VLPs can be successfully purified with ~31  52% yield and >95% purity. They could elicit stronger neutralization antibodies in @entity19 compared with those produced from @entity406 -inactivated EV71 virus. CONCLUSIONS: Our results demonstrated that EV71 VLPs can be purified with the multistep chromatographic protocol. SIGNIFICANCE AND IMPACT OF THE STUDY: This work presents a novel multistep chromatographic technique, an effective way of purifying EV71 VLPs with high purity. This purification process can thus serve as foundation for further development of industrial-scale production process of EV71 VLP vaccine candidates.

title: Enterovirus71 virus-like particles produced from insect cells and purified by multistep chromatography elicit strong humoral immune responses in XXXX .

entities_list: @entity406 :: ('MESH:D005557', 'Chemical') :: ['formalin']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infection']

answer: @entity19 :: (10090,Species) :: ['mice']


abstract: The study aimed to investigate whether we can stop antibiotic therapy when signs and symptoms have resolved in @entity6 ( @entity6 ) @entity1 with different grades of @entity3657 ( @entity3657 ) and those without @entity3657 , and to determine whether the severity of @entity3657 and @entity281 has an effect on antibiotic therapy duration. A prospective randomized controlled trial of @entity6 @entity1 was carried out. @entity1 were randomized into 2 groups when signs and symptoms had resolved: continuing antibiotics group (CAG) and discontinuing antibiotics group (DAG). The recurrence and clinical outcomes were recorded. The recurrence rate of mild @entity281 with mild/moderate @entity3657 was similar in the 2 groups. Compared with CAG, the recurrence rate of mild @entity281 with severe @entity3657 was higher in DAG (P = .030), also for moderate/severe @entity281 with @entity3657 (mild/moderate [P = .032]; severe [P = .008]). No difference was found in the 2 groups (either mild or moderate/severe) for those without @entity3657 . The clinical outcomes of mild @entity281 in @entity1 were similar in the 2 groups. For moderate/severe @entity281 , the healing rate was higher (73.3% vs 48.3%), and the rate of minor/major amputation and @entity204 was lower (23.8% vs 49.4%; 6.9% vs 20.7%; 2.0% vs 13.8%) in the CAG. When the clinical signs and symptoms of @entity281 have resolved, it might be appropriate to stop antibiotics for @entity6 @entity1 without @entity3657 , and also for @entity1 with mild @entity281 with mild/moderate @entity3657 . For @entity1 with mild @entity281 with severe @entity3657 and moderate/severe @entity281 with @entity3657 , we should perhaps continue antibiotic treatment. Continuing antibiotic therapy could improve clinical outcomes for @entity1 with moderate/severe @entity281 .

title: Can We Stop Antibiotic Therapy When Signs and Symptoms Have Resolved in XXXX @entity1 ?

entities_list: @entity3657 :: ('MESH:D058729', 'Disease') :: ['PAD', 'peripheral arterial disease']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['DFI', 'diabetic foot infection']

answer: @entity6 :: (MESH:D003920,Disease) :: ['Diabetic Foot Infection']


abstract: The study aimed to investigate whether we can stop antibiotic therapy when signs and symptoms have resolved in @entity6 ( @entity6 ) @entity1 with different grades of @entity3657 ( @entity3657 ) and those without @entity3657 , and to determine whether the severity of @entity3657 and @entity281 has an effect on antibiotic therapy duration. A prospective randomized controlled trial of @entity6 @entity1 was carried out. @entity1 were randomized into 2 groups when signs and symptoms had resolved: continuing antibiotics group (CAG) and discontinuing antibiotics group (DAG). The recurrence and clinical outcomes were recorded. The recurrence rate of mild @entity281 with mild/moderate @entity3657 was similar in the 2 groups. Compared with CAG, the recurrence rate of mild @entity281 with severe @entity3657 was higher in DAG (P = .030), also for moderate/severe @entity281 with @entity3657 (mild/moderate [P = .032]; severe [P = .008]). No difference was found in the 2 groups (either mild or moderate/severe) for those without @entity3657 . The clinical outcomes of mild @entity281 in @entity1 were similar in the 2 groups. For moderate/severe @entity281 , the healing rate was higher (73.3% vs 48.3%), and the rate of minor/major amputation and @entity204 was lower (23.8% vs 49.4%; 6.9% vs 20.7%; 2.0% vs 13.8%) in the CAG. When the clinical signs and symptoms of @entity281 have resolved, it might be appropriate to stop antibiotics for @entity6 @entity1 without @entity3657 , and also for @entity1 with mild @entity281 with mild/moderate @entity3657 . For @entity1 with mild @entity281 with severe @entity3657 and moderate/severe @entity281 with @entity3657 , we should perhaps continue antibiotic treatment. Continuing antibiotic therapy could improve clinical outcomes for @entity1 with moderate/severe @entity281 .

title: Can We Stop Antibiotic Therapy When Signs and Symptoms Have Resolved in @entity6 XXXX ?

answer: @entity1 :: (9606,Species) :: ['Patients']


abstract: OBJECTIVE: To review and synthesize the evidence on the use of @entity419 -PET in the assessment and treatment of nine types of @entity5 with respect to the following clinical situations: diagnosis, @entity5 , restaging, and monitoring response to treatment. DATA SOURCES: Comprehensive searches were conducted in four relevant electronic databases for the time period from 2003 to March 2008. REVIEW METHODS: Studies should be published in English, with more than 12 adult @entity1 with primary @entity5 of the following type: bladder, brain, cervical, kidney, ovarian, pancreatic, prostate, small cell lung, and testicular. Restrictions regarding study design were not imposed. Two independent reviewers assessed study relevance, extracted the data and assessed the methodological quality of the studies. A combination of qualitative and quantitative approaches was used to synthesize the data. RESULTS: One hundred and nine articles were included in this report. The strongest evidence for the diagnostic accuracy of @entity419 -PET or @entity419 -PET/CT has been produced for @entity5 of locally advanced cervical @entity5 and the detection and restaging of recurrent disease, the detection of @entity43 recurrences following treatment, and the diagnosing and initial @entity5 of @entity788 . These and other indications require further research to show the impact of @entity419 -PET or @entity419 -PET/CT on @entity1 management or added value in the diagnostic and therapeutic process. CONCLUSION: For some type of @entity5 (e.g., cervical, ovarian, and @entity788 ), there is some evidence of the utility of @entity419 -PET or @entity419 -PET/CT for diagnosing, @entity5 , or detecting recurrences, but they may still require more studies to augment the evidence base. Further studies are needed to reach firm conclusions about the clinical effectiveness of @entity419 -PET and @entity419 -PET/CT in terms of the impact on diagnosis and treatment options, @entity1 -centered outcomes, and economic costs. It is still unclear how @entity419 -PET and @entity419 -PET/CT affects @entity1 treatment and ultimately their outcome. For other types of @entity5 examined in the review (e.g., bladder, kidney, prostate, @entity4153 , and testicular) the answers are still inconclusive and require more careful study.

title: Positron Emission Tomography for Nine XXXX (Bladder, Brain, Cervical, Kidney, Ovarian, Pancreatic, Prostate, Small Cell Lung, Testicular)

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'patient']

entities_list: @entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian cancer']

entities_list: @entity788 :: ('MESH:D010190', 'Disease') :: ['pancreatic cancer']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancers', 'cancer', 'staging']

answer: @entity5 :: (MESH:D009369,Disease) :: ['Cancers']